Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)

SHE:300267 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	686.06	698.54	744.35	764.67	761.56	883.22
Short-Term Investments	-	-	-	-	-	400
Trading Asset Securities	20	120	0.12	114.12	-	5.3
Cash & Short-Term Investments	706.06	818.54	744.47	878.79	761.56	1,289
Cash Growth	31.93%	9.95%	-15.28%	15.39%	-40.90%	-5.94%
Accounts Receivable	168.09	198.3	177.8	204.48	274.36	422.08
Other Receivables	55.85	4.46	18.17	27.81	13.57	4.48
Receivables	223.94	202.77	195.97	232.29	287.93	426.56
Inventory	670.92	600.78	691.6	821.34	714.77	756.06
Prepaid Expenses	-	-	1.39	-	-	-
Other Current Assets	75.8	95	97.58	158.78	182.1	214.63
Total Current Assets	1,677	1,717	1,731	2,091	1,946	2,686
Property, Plant & Equipment	2,691	2,716	2,917	2,857	2,604	3,026
Long-Term Investments	121.73	121.74	170.23	188.97	196.16	155.96
Goodwill	2	2	2	10.01	10.01	23.84
Other Intangible Assets	359.18	363.56	378.03	406.14	431.45	553.35
Long-Term Deferred Tax Assets	148.94	150.55	152.14	168.92	118.34	58.97
Long-Term Deferred Charges	10.35	10.66	12.08	19.5	16.51	13.96
Other Long-Term Assets	114.49	117.78	116.25	114.6	108.75	138.93
Total Assets	5,124	5,200	5,479	5,856	5,432	6,657
Accounts Payable	121.5	114.66	122.3	198.7	137.87	152.23
Accrued Expenses	9.29	26.09	31.22	23.38	33.79	24.66
Short-Term Debt	401.26	488.2	341.89	396.64	246	463
Current Portion of Leases	3.69	3.69	2.16	4.11	3.88	-
Current Income Taxes Payable	2.38	0.17	0.99	0.97	0.74	5.03
Current Unearned Revenue	44.89	29.82	47.01	51.31	37.35	33.89
Other Current Liabilities	35.81	42.71	57.73	50.33	39.3	76.97
Total Current Liabilities	618.82	705.34	603.3	725.43	498.93	755.78
Long-Term Leases	17.09	17.38	1.17	2.58	2.15	-
Long-Term Unearned Revenue	13.69	14.93	18.39	23.15	27.91	34.01
Long-Term Deferred Tax Liabilities	46.98	46.9	46.2	53.41	29.29	29.05
Other Long-Term Liabilities	12.99	12.99	-	-	-	-
Total Liabilities	709.57	797.54	669.05	804.57	558.28	818.84
Common Stock	2,063	2,063	2,063	2,063	2,063	2,063
Additional Paid-In Capital	1,019	1,019	1,019	1,005	998.96	1,024
Retained Earnings	1,332	1,304	1,677	1,935	1,889	2,783
Comprehensive Income & Other	49.98	61.27	76.52	48.34	-99.15	-58.39
Total Common Equity	4,464	4,447	4,836	5,051	4,851	5,811
Minority Interest	-49.48	-45.23	-26.03	0.27	22.49	27.11
Shareholders' Equity	4,415	4,402	4,810	5,051	4,874	5,838
Total Liabilities & Equity	5,124	5,200	5,479	5,856	5,432	6,657
Total Debt	422.04	509.27	345.21	403.33	252.04	463
Net Cash (Debt)	284.02	309.27	399.25	475.46	509.53	825.53
Net Cash Growth	56.60%	-22.54%	-16.03%	-6.69%	-38.28%	-39.74%
Net Cash Per Share	0.14	0.15	0.19	0.23	0.25	0.40
Filing Date Shares Outstanding	2,063	2,063	2,063	2,063	2,063	2,063
Total Common Shares Outstanding	2,063	2,063	2,063	2,063	2,063	2,063
Working Capital	1,058	1,012	1,128	1,366	1,447	1,930
Book Value Per Share	2.16	2.16	2.34	2.45	2.35	2.82
Tangible Book Value	4,103	4,082	4,456	4,635	4,410	5,234
Tangible Book Value Per Share	1.99	1.98	2.16	2.25	2.14	2.54
Buildings	-	1,933	1,990	1,926	1,740	2,035
Machinery	-	1,914	1,878	1,896	1,224	1,447
Construction In Progress	-	174.58	220.89	52.92	506.18	408.21

Source: S&P Global Market Intelligence. Standard template. Financial Sources.